Compare NANO MRNA Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of -15.68% over the last 5 years
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 7,764 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.03
-31.21%
2.90
Revenue and Profits:
Net Sales:
90 Million
(Quarterly Results - Dec 2025)
Net Profit:
-207 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.0%
0%
-40.0%
6 Months
-31.08%
0%
-31.08%
1 Year
-19.69%
0%
-19.69%
2 Years
-40.7%
0%
-40.7%
3 Years
-55.07%
0%
-55.07%
4 Years
-61.65%
0%
-61.65%
5 Years
-67.62%
0%
-67.62%
NANO MRNA Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-15.68%
EBIT Growth (5y)
2.94%
EBIT to Interest (avg)
-1,100.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.08
Sales to Capital Employed (avg)
0.03
Tax Ratio
0.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.84
EV to EBIT
-11.68
EV to EBITDA
-11.68
EV to Capital Employed
-109.65
EV to Sales
65.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-31.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
89.80
33.40
168.86%
Operating Profit (PBDIT) excl Other Income
-203.80
-209.30
2.63%
Interest
0.00
0.00
Exceptional Items
0.00
-54.20
100.00%
Consolidate Net Profit
-207.30
-239.30
13.37%
Operating Profit Margin (Excl OI)
-2,268.40%
-6,267.80%
399.94%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 168.86% vs 333.77% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 13.37% vs -19.11% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
108.50
135.50
-19.93%
Operating Profit (PBDIT) excl Other Income
-755.30
-863.30
12.51%
Interest
0.00
0.00
Exceptional Items
-145.00
-71.30
-103.37%
Consolidate Net Profit
-835.40
-780.00
-7.10%
Operating Profit Margin (Excl OI)
-6,960.70%
-6,379.10%
-58.16%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -19.93% vs -32.99% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -7.10% vs 40.50% in Mar 2024
About NANO MRNA Co., Ltd. 
NANO MRNA Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






